JENLOGA Drug Patent Profile

Which patents cover Jenloga, and what generic alternatives are available?

Jenloga is a drug marketed by Concordia Pharms Inc and is included in one NDA.

The generic ingredient in JENLOGA is clonidine hydrochloride. There are twenty-two drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the clonidine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Jenloga

A generic version of JENLOGA was approved as clonidine hydrochloride by ACTAVIS ELIZABETH on December 16^th, 1986.

Summary for JENLOGA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	111
Patent Applications:	2,778
DailyMed Link:	JENLOGA at DailyMed

US Patents and Regulatory Information for JENLOGA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Concordia Pharms Inc	JENLOGA	clonidine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022331-001	Sep 30, 2009		DISCN	Yes	No
Concordia Pharms Inc	JENLOGA	clonidine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022331-002	May 25, 2010		DISCN	Yes	No

Expired US Patents for JENLOGA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Concordia Pharms Inc	JENLOGA	clonidine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022331-001	Sep 30, 2009	5,869,100
Concordia Pharms Inc	JENLOGA	clonidine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	022331-002	May 25, 2010	5,869,100

International Patents for JENLOGA

See the table below for patents covering JENLOGA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	5259396
Spain	2245782
Germany	69534283
Australia	707843
World Intellectual Property Organization (WIPO)	9622768
European Patent Office	0805677	PREPARATION DE CLONIDINE A LIBERATION PROLONGEE (EXTENDED RELEASE CLONIDINE FORMULATION)

Market Dynamics and Financial Trajectory for JENLOGA

Last updated: February 20, 2026

What is JENLOGA?

JENLOGA (ertugliflozin) is an SGLT2 inhibitor approved by the FDA for the treatment of type 2 diabetes mellitus. Developed by Merck & Co., it is marketed under the brand name JENLOGA. It functions by promoting renal glucose excretion, leading to improved glycemic control.

Market Size and Growth Drivers

Global Diabetes Treatment Market

The global market for diabetes medications reached approximately USD 85 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7% through 2030. The growth factors include increasing diabetes prevalence, expanding aging populations, and innovative drug approvals.

SGLT2 Inhibitors Market

Within the broader diabetes market, SGLT2 inhibitors commanded USD 16 billion in 2022, with a CAGR of 14%. This class experienced rapid expansion due to favorable cardiovascular and renal outcome data.

JENLOGA’s Position

JENLOGA captured an estimated USD 650 million in sales in 2022, accounting for roughly 4% of the SGLT2 inhibitor market. Its market share benefits from Merck's established commercialization channels and pricing strategies.

Regulatory and Competitive Landscape

Regulatory Status

• FDA approval granted in June 2019.
• EMA approval obtained in April 2020.
• Approved in select Asian markets from 2021 onward.

Competitiveness

JENLOGA faces competition primarily from:

• Jardiance (empagliflozin): Leading SGLT2 inhibitor with USD 7.3 billion in 2022 sales.
• Invokana (canagliflozin): USD 4.6 billion in 2022 sales.
• Steglatro (ertugliflozin): Merck's own product, primarily launched in some markets.

JENLOGA’s differentiated features include specific renal and cardiovascular benefit profiles, but its market penetration remains modest compared to Jardiance and Invokana.

Pricing and Reimbursement

Pricing

Average wholesale price (AWP):

• JENLOGA: USD 5.50 per day.
• Jardiance: USD 6.20 per day.
• Invokana: USD 5.80 per day.

Reimbursement

Coverage varies by payer and geography. In the U.S., Medicare Part D covers most SGLT2 inhibitors with favorable tier placement. In emerging markets, reimbursement policies are evolving, influencing sales.

Revenue Outlook and Financial Trajectory

Short-Term Projections (Next 2 Years)

• Expected revenues: USD 900 million to USD 1.2 billion.
• Growth driven by expanded indications (e.g., cardiovascular benefits), increased market penetration, and geographic expansion.

Long-Term Projections (Next 5 Years)

• Revenue estimates: USD 2 billion to USD 3 billion.

• Market share growth influenced by:

  • Broader mineral and renal disease approvals.
  • Combination therapy positioning.
  • Competition evolution with next-generation agents.

Risks and Challenges

• Patent expirations possibly starting in 2027.
• Competitive innovations delivering superior efficacy or safety profiles.
• Regulatory shifts impacting label expansions.

Financial Milestones and Investment Implications

• Merck’s R&D expenditure on ergotliflozin: USD 150 million annually.
• Marketing and commercialization costs: USD 75 million annually.
• Investment in geographic expansion prioritized in emerging markets.

External Factors

• Changes in healthcare policies or reimbursement.
• Market adoption slowdowns due to safety concerns or adverse events.
• Impact of COVID-19 on supply chains and healthcare delivery.

Regulatory and Market Trends Impacting JENLOGA

Trend	Effect
Cardiovascular outcome mandates	Drive demand due to proven benefits in CV risk reduction.
Personalized medicine	Favor drugs with specific safety profiles for subpopulations.
Emerging markets	Accelerate growth given rising diabetes prevalence.
Biosimilars and generics	Lower prices and potential share erosion post-patent expiry.

Key Takeaways

• JENLOGA has established a niche within the expanding SGLT2 inhibitor market.
• Market growth prospects remain robust, supported by cardiovascular and renal benefits.
• Competition from Jardiance and Invokana limits market share; differentiation strategies are crucial.
• Revenue growth hinges on geographic expansion, effective pricing, and label expansions.
• Patent landscapes and regulatory environments pose risks to long-term profitability.

FAQs

1. What are the primary advantages of JENLOGA compared to other SGLT2 inhibitors?
   JENLOGA offers specific renal and cardiovascular benefits, with a safety profile tailored for certain patient subgroups. Its dosing flexibility may provide additional clinical advantages.

2. When are patent expirations expected for JENLOGA?
   Patent protections are likely to expire around 2027-2029 in key markets, opening opportunities for generics.

3. What are the key regulatory challenges for JENLOGA?
   Label expansions for additional indications, such as heart failure or renal disease, depend on positive outcomes from ongoing trials and regulatory approval processes.

4. How does pricing influence JENLOGA’s market adoption?
   Competitive pricing relative to peers impacts payer acceptance, especially in cost-conscious markets. Reimbursement policies will significantly influence access.

5. What market segments present the highest growth potential for JENLOGA?
   Emerging markets with rising diabetes prevalence, patients with renal comorbidities, and those eligible for combination therapies offer substantial upside.

References

[1] IQVIA. (2023). Global Diabetes Market Report.
[2] Merck & Co.. (2023). JENLOGA Product Information.
[3] Statista. (2022). Market Share of SGLT2 Inhibitors Worldwide.
[4] FDA. (2019). Approval Announcement for JENLOGA.
[5] EvaluatePharma. (2023). Pharmaceutical Sales and Market Data.